DZ2518A1 - Inhibiteurs de farnésyl - transférase en association avec des inhibiteurs de HMG-Coa-reductase pour le traitement du cancer. - Google Patents

Inhibiteurs de farnésyl - transférase en association avec des inhibiteurs de HMG-Coa-reductase pour le traitement du cancer.

Info

Publication number
DZ2518A1
DZ2518A1 DZ980128A DZ980128A DZ2518A1 DZ 2518 A1 DZ2518 A1 DZ 2518A1 DZ 980128 A DZ980128 A DZ 980128A DZ 980128 A DZ980128 A DZ 980128A DZ 2518 A1 DZ2518 A1 DZ 2518A1
Authority
DZ
Algeria
Prior art keywords
inhibitors
hmg
coa
cancer
treatment
Prior art date
Application number
DZ980128A
Other languages
English (en)
Inventor
Shama Mohammed Kajiji
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of DZ2518A1 publication Critical patent/DZ2518A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DZ980128A 1997-06-16 1998-06-15 Inhibiteurs de farnésyl - transférase en association avec des inhibiteurs de HMG-Coa-reductase pour le traitement du cancer. DZ2518A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4963897P 1997-06-16 1997-06-16

Publications (1)

Publication Number Publication Date
DZ2518A1 true DZ2518A1 (fr) 2003-02-01

Family

ID=21960890

Family Applications (1)

Application Number Title Priority Date Filing Date
DZ980128A DZ2518A1 (fr) 1997-06-16 1998-06-15 Inhibiteurs de farnésyl - transférase en association avec des inhibiteurs de HMG-Coa-reductase pour le traitement du cancer.

Country Status (37)

Country Link
EP (1) EP0986387B1 (fr)
JP (1) JP3713051B2 (fr)
KR (1) KR100392573B1 (fr)
CN (1) CN1259868A (fr)
AP (1) AP9801261A0 (fr)
AR (1) AR013090A1 (fr)
AT (1) ATE235905T1 (fr)
BG (1) BG103946A (fr)
BR (1) BR9810616A (fr)
CA (1) CA2294399C (fr)
CO (1) CO4950607A1 (fr)
DE (1) DE69812933T2 (fr)
DK (1) DK0986387T3 (fr)
DZ (1) DZ2518A1 (fr)
EA (1) EA199901043A1 (fr)
ES (1) ES2196559T3 (fr)
GT (1) GT199800081A (fr)
HN (1) HN1998000091A (fr)
HR (1) HRP980328B1 (fr)
HU (1) HUP0004624A3 (fr)
ID (1) ID23014A (fr)
IL (1) IL132765A0 (fr)
IS (1) IS5259A (fr)
MA (1) MA24569A1 (fr)
NO (1) NO996206L (fr)
NZ (1) NZ500662A (fr)
OA (1) OA11231A (fr)
PA (1) PA8453601A1 (fr)
PE (1) PE82899A1 (fr)
PL (1) PL337651A1 (fr)
PT (1) PT986387E (fr)
SK (1) SK169699A3 (fr)
TN (1) TNSN98088A1 (fr)
TR (1) TR199903074T2 (fr)
UA (1) UA57081C2 (fr)
WO (1) WO1998057633A1 (fr)
ZA (1) ZA985182B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492410B1 (en) 1998-05-12 2002-12-10 Warner-Lambert Company Combinations of protein farnesyltransferase and HMG CoA reductase inhibitors and their use to treat cancer
WO2000016778A1 (fr) * 1998-09-24 2000-03-30 Merck & Co., Inc. Procede de traitement du cancer
EP1006113A1 (fr) 1998-12-02 2000-06-07 Pfizer Products Inc. Dérivés de 2-(2-oxo-éthylidène)-imidazolidin-4-one et leur utilisation pour inhiber la croissance anormale des cellules
AU4988100A (en) * 1999-05-07 2000-11-21 Brigham And Women's Hospital Use of hmgcoa reductase inhibitors in the prevention of diseases whose pathogenesis is dependent on neovascularization
US6710058B2 (en) 2000-11-06 2004-03-23 Bristol-Myers Squibb Pharma Company Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors
WO2002050058A1 (fr) 2000-12-19 2002-06-27 Pfizer Products Inc. Formes cristallines de sels de 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-(3-ethynyl-phenyl)-1-methyl-1h-quinoleine-2-one, 2,3-dihydroxybutanedioate et procede de preparation
CA2432642A1 (fr) 2000-12-21 2002-08-08 Subhash P. Khanapure Composes aryle substitues en tant que nouveaux inhibiteurs selectifs de la cyclo-oxygenase-2, compositions et methodes d'utilisation
US20020151563A1 (en) * 2001-03-29 2002-10-17 Pfizer Inc. Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth
US6740757B2 (en) 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
TWI297606B (en) * 2004-01-16 2008-06-11 Nat Health Research Institutes Cancer therapy
US8168667B2 (en) 2006-05-31 2012-05-01 Galapagos Nv Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such
GB2463514C (en) 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083985A (en) * 1995-08-09 2000-07-04 Banyu Pharmaceutical Co., Ltd. Medicinal composition

Also Published As

Publication number Publication date
TNSN98088A1 (fr) 2005-03-15
AR013090A1 (es) 2000-12-13
DK0986387T3 (da) 2003-07-14
GT199800081A (es) 1999-12-07
HUP0004624A3 (en) 2002-11-28
AP9801261A0 (en) 1999-12-11
NO996206D0 (no) 1999-12-15
NZ500662A (en) 2001-10-26
PE82899A1 (es) 1999-08-26
JP2000513031A (ja) 2000-10-03
ZA985182B (en) 1999-12-17
WO1998057633A1 (fr) 1998-12-23
DE69812933T2 (de) 2003-11-06
CA2294399A1 (fr) 1998-12-23
EA199901043A1 (ru) 2000-06-26
TR199903074T2 (xx) 2000-05-22
ES2196559T3 (es) 2003-12-16
BG103946A (bg) 2000-07-31
PA8453601A1 (es) 2000-05-24
CA2294399C (fr) 2004-03-16
AU724676B2 (en) 2000-09-28
DE69812933D1 (de) 2003-05-08
PL337651A1 (en) 2000-08-28
CO4950607A1 (es) 2000-09-01
EP0986387B1 (fr) 2003-04-02
HN1998000091A (es) 1999-09-29
IS5259A (is) 1999-11-19
UA57081C2 (uk) 2003-06-16
ID23014A (id) 1999-12-30
ATE235905T1 (de) 2003-04-15
MA24569A1 (fr) 1998-12-31
BR9810616A (pt) 2000-09-12
NO996206L (no) 2000-02-15
PT986387E (pt) 2003-06-30
HUP0004624A2 (hu) 2001-10-28
AU7445998A (en) 1999-01-04
HRP980328B1 (en) 2002-06-30
KR100392573B1 (ko) 2003-07-23
SK169699A3 (en) 2000-06-12
IL132765A0 (en) 2001-03-19
OA11231A (en) 2003-05-26
EP0986387A1 (fr) 2000-03-22
KR20010013839A (ko) 2001-02-26
JP3713051B2 (ja) 2005-11-02
HRP980328A2 (en) 1999-04-30
CN1259868A (zh) 2000-07-12

Similar Documents

Publication Publication Date Title
CY2006007I2 (el) Χρηση αναστολεων cgmp-φωσφοδιεστερασης στην αγωγη της ανικανοτητας
HK1037981A1 (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis C.
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
MX9700534A (es) Uso de droloxifeno y sus sales farmaceuticamente aceptables en la preparacion de remedios para tratar las enfermedades de prostata, endometriosis y obesidad.
DZ2518A1 (fr) Inhibiteurs de farnésyl - transférase en association avec des inhibiteurs de HMG-Coa-reductase pour le traitement du cancer.
HK1036279A1 (en) Farnesyl protein transferase inhibitors.
IT1285874B1 (it) Metodo per giudicare le proprieta' di ghisa fusa.
ZA964762B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
ZA964761B (en) Peptidyl heterocycles useful in the treatment of thrombin related disorders.
DZ2665A1 (fr) Conjugués utiles pour le traitement du cancer de la prostate.
IS2253B (is) Notkun á eletriptani til fyrirbyggingar á endurteknu mígreni
TR200103125T2 (tr) Otizmin iyileştirilmesinde kullanıma yönelik antikonvülsan türevleri.
FI953825A (fi) Tyhjennysventtiili
FR2752924B3 (fr) Clayette pour refrigerateurs
FR2721930B1 (fr) Oligonucleotides pour inhiber le role des isoprenyl proteine transferases
FR2715715B1 (fr) Améliorations introduites dans les circuits de dégazage des radiateurs.
DE29618472U1 (de) Vorrichtung zur Aufbereitung von Trinkwasser
MXPA03002280A (es) Proceso para purificacion de isooctano y/o diisobutileno.
FR2804331B1 (fr) Valve pour le traitement de l'hydrocephalie
BR7601412U (pt) Aparelho aplicável no tratamento de fluxo de graos em geral
KR960007932U (ko) 생수통
ES1038007Y (es) Determinador cromatico del nivel de hierro en cerdas de cria.
GB9825969D0 (en) Agents useful in the treatment of reproductive disorders
KR960005053U (ko) 생수용기 밀페캡
SE9101363D0 (sv) Foerfarande foer minskning av resthalt av metall i dricksvatten